Living with NMOSD
Factors influencing their well-being negatively include pain, inability to work and reduced sexual function.1 Also dissatisfaction with treatment options and economic burden correlate with their quality of life (QoL).1
* A retrospective study of a US administrative claims database (n = 1349). Data presented here are from patients with highly active NMOSD (n=134) with at least two relapses in the 12 months following the index date.2
< 70%

* Cross-sectional survey design study was conducted using validated instruments to assess physical, emotional, and socioeconomic burden of NMOSD on QoL among 193 patients.1

† n = 100/193.1
* Assessment of physical, emotional, and socioeconomic burden of NMOSD on QoL among 193 patients.11
† Each determinant represents the mean on a scale of 1–5, 1–6, or 1–10. The higher the mean score on the scale, the more the patient perceived NMOSD has impacted that particular aspect of their life.11

28% of patients living with NMOSD report experiencing moderate–to–severe depression.*6
* Based on an observational study of 71 patients diagnosed with NMOSD.12
Learn more
NMOSD, neuromyelitis optica spectrum disorder; QoL, quality of life.
Beekman J, et al. Neuromyelitis optica spectrum disorder: Patient experience and quality of life. Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e580. Ajmera MR, et al. Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. J Neurol Sci. 2018;384:96–103. Jarius S, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J. Neuroinflammation. 2012;9(1):14. Brod SA. Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. Mult Scler Relat Disord. 2020;46:102538. Jasiak–Zatonska M, et al. The immunology of neuromyelitis optica- Current knowledge, clinical implications, controversies and future implications. Int J Mol Sci. 2016;17(3):273. Mandler RN, Neuromyelitis optica- Delvic’s syndrome, update. Autoimmun Rev; 2006;5(8):537–543. Chavarro VS, et al. Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016;3:e286. Ma X, et al. Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventative strategy. Mult Scler Relat Disord; 2020;46:102522. Jiao Y, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology; 2013;81(14):1197–1204. Kitley J, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain; 2012;135(pt 6):1834–1849. Eaneff S, et al. Patient perspectives on neuromyelitis optica spectrum disorders: Data from the Patientslikeme online survey. Mult Scler Relat Disord; 2017;17:116–122. Royston M, et al. Neuromyelitis optica spectrum disorder: Clinical burden and cost of relapses and disease-related care in US clincial practice. Neurol Ther; 2021;10(2):767–783. advance I am a healthcare professional registered in the EU I am not a
healthcare professional